September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Patient satisfaction related to tolerance when treated with preservative-free latanoprost; results from the PASSY survey in six European countries
Author Affiliations & Notes
  • Hans G Lemij
    Ophthalmology, Rotterdam Eye Hosp (Oogziekenhuis Rotterdam), Rotterdam, Netherlands
  • Ingeborg Stalmans
    University Hospitals Leuven, Leuven, Belgium
  • Carl Erb
    Augenklinik am Wittenbergplatz, Berlin, Germany
  • Francisco Munoz
    Ramon y Cajal Hospital, Madrid, Spain
  • Footnotes
    Commercial Relationships   Hans Lemij, Alcon (F), Carl Zeiss Meditec (F), Heidelberg Engineering (F), Optovue (F), Théa Pharma (C), Topcon (F); Ingeborg Stalmans, Alcon (C), Alimera (C), Allergan (C), Amekem (C), AqueSys (C), EyeTechCare (C), Isarna (C), Santen (C), Théa (C); Carl Erb, None; Francisco Munoz, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3026. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Hans G Lemij, Ingeborg Stalmans, Carl Erb, Francisco Munoz; Patient satisfaction related to tolerance when treated with preservative-free latanoprost; results from the PASSY survey in six European countries. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3026.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : Patient satisfaction was previously assessed in a European population receiving mainly preserved topical treatment. The PASSY survey (Patient Satisfaction SurveY) was undertaken in 6 European countries to evaluate patient satisfaction and medication tolerance after switching to PF (preservative free) latanoprost eyedrops.

Methods : PASSY is an International, epidemiological, retrospective survey. OHT/glaucoma patients who received a PF latanoprost (Monoprost®) for 3 months were included. The following data were collected: glaucoma history, previous treatment, reasons for change, tolerance, patient satisfaction, ocular signs, ocular surface disease, ease of use and tear substitute use.

Results : 1872 patients from Belgium, Germany, Netherlands, Portugal, Spain and Switzerland participated in the survey. 68.7% were previously treated with preserved eyedrops and 23.6% were treatment naive. The two main reasons for treatment change were local intolerance (61.8%) and insufficient efficacy (49.1%).
Regarding tolerance, 95% of the patients previously treated with preserved eyedrops declared to be satisfied or very satisfied with PF latanoprost (P<0.0001). This percentage reached 97.3% in naive patients. In comparison to the previous treatment, 73.5% of the patients considered that PF latanoprost was better or much better tolerated (P<0.0001), and for 22% of them, the tolerance was the same. The tolerance was also evaluated with a Visual Analog Scale (VAS) (0 mm: very bad tolerance – 100 mm: very good tolerance). The mean VAS was 83.5 mm (SD=16.5) for PF latanoprost and 57.7 mm (SD=27.2) for the previous treatment. The VAS global improvement was + 25.8 mm (45% of increase after switch).
PF latanoprost unidoses were considered as easier or much easier to use (P<0.0001) than the packaging of the previous glaucoma treatment by 40.7% of the patients and as equal by 48.8%.
Before the switch, 45.4% of patients used artificial tears. The use of artificial tears decreased in 24.1% of the users after switching to PF latanoprost and in 68% the use was unchanged (P<0.0001).

Conclusions : After 3 months of Monoprost® treatment, patients appeared to be more satisfied, to need fewer artificial tears and the vast majority judged that the unidoses were at least as easy to use as the packaging of the previous treatment.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.